1. Home
  2. KALV

as 06-20-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

Founded: N/A Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 476.7M IPO Year: N/A
Target Price: $25.00 AVG Volume (30 days): 250.6K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.13 EPS Growth: N/A
52 Week Low/High: $7.21 - $16.88 Next Earning Date: 07-05-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

KALV Daily Stock ML Predictions

Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Feener Edward P. KALV CHIEF SCIENTIFIC OFFICER May 17 '24 Sell $11.76 8,088 $95,151.28 72,858 SEC Form 4
Audhya Paul K. KALV CHIEF MEDICAL OFFICER May 17 '24 Sell $11.76 13,175 $154,997.29 70,325 SEC Form 4
Palleiko Benjamin L KALV CHIEF EXECUTIVE OFFICER May 17 '24 Sell $11.76 21,959 $258,336.66 216,387 SEC Form 4
Yea Christopher KALV CHIEF DEVELOPMENT OFFICER May 17 '24 Sell $11.76 11,610 $136,585.85 80,074 SEC Form 4
Palleiko Benjamin L KALV CFO, CBO Feb 17 '24 Sell $14.11 22,802 $321,845.67 187,315 SEC Form 4
Crockett Thomas Andrew KALV CEO Feb 17 '24 Sell $14.11 24,888 $351,289.14 211,203 SEC Form 4
Audhya Paul K. KALV CHIEF MEDICAL OFFICER Feb 17 '24 Sell $14.12 14,295 $201,773.93 52,886 SEC Form 4
Feener Edward P. KALV CHIEF SCIENTIFIC OFFICER Feb 17 '24 Sell $14.11 8,397 $118,521.98 82,048 SEC Form 4
Feener Edward P. KALV CHIEF SCIENTIFIC OFFICER Feb 17 '24 Sell $14.04 19,591 $274,991.03 62,457 SEC Form 4
Feener Edward P. KALV CHIEF SCIENTIFIC OFFICER Feb 17 '24 Sell $14.72 300 $4,416.00 62,157 SEC Form 4
Feener Edward P. KALV CHIEF SCIENTIFIC OFFICER Feb 14 '24 Sell $15.01 28,171 $422,826.99 71,657 SEC Form 4
Yea Christopher KALV CHIEF DEVELOPMENT OFFICER Feb 14 '24 Sell $15.01 39,886 $598,660.94 66,160 SEC Form 4
Crockett Thomas Andrew KALV CEO Feb 14 '24 Sell $15.01 58,356 $875,882.71 181,676 SEC Form 4
Palleiko Benjamin L KALV CFO, CBO Feb 14 '24 Sell $15.01 40,855 $613,204.95 159,088 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Feb 6 '24 Buy $14.74 4,474 $65,946.76 4,743,157 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Feb 6 '24 Buy $14.56 51,827 $754,601.12 4,794,984 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Feb 6 '24 Buy $14.70 29,747 $437,280.90 4,824,731 SEC Form 4
Crockett Thomas Andrew KALV CEO Feb 1 '24 Sell $16.18 9,300 $150,428.43 118,232 SEC Form 4
Crockett Thomas Andrew KALV CEO Feb 1 '24 Sell $16.81 700 $11,770.01 117,532 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 30 '24 Buy $14.47 88,099 $1,274,792.53 4,738,683 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 25 '24 Buy $12.73 7,030 $89,491.90 4,565,810 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 25 '24 Buy $12.98 4,174 $54,178.52 4,569,984 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 25 '24 Buy $14.22 80,600 $1,146,132.00 4,650,584 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 22 '24 Buy $12.55 67,546 $847,702.30 4,527,197 SEC Form 4
Venrock Healthcare Capital Partners III, L.P. KALV 10% Owner Jan 22 '24 Buy $12.54 10,897 $136,648.38 4,538,094 SEC Form 4

Share on Social Networks: